Catalent's newly appointed CEO, Alessandro Maselli, experienced the highs of the pharmaceutical contract development manufacturing (CDMO) space during COVID-19 while helping Moderna and others bring vaccines to market quickly and safely. After rushing to add capacity to help deal with the pandemic, demand for CDMO services dried up post-pandemic, leaving Maselli and Catalent to pick up the pieces. Once considered as an acquisition target by other industry giants, Catalent dealt with several struggles, including a departing CFO, several issues with plants, and declining demand. How can Maselli turn the ship around and drive Catalent to even higher heights moving forward?